Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

Journal of Urology

Volumn 163, Issue 3, 2000, Pages 834-837

  Weitzman, Aaron L ^a   Shelton, Gary ^a   Zuech, Nancy ^a   Owen, Cindy England ^a   Judge, Timothy ^a   Benson, Mitchell ^a   Sawczuk, Ihor ^a   Katz, Aaron ^a   Olsson, Carl A ^a   Bagiella, Emilia ^a   Pfaff, Charles ^a   Newhouse, Jeffrey H ^a   Petrylak, Daniel P ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Dexamethasone; Estramustine; Prostate; Prostatic neoplasms

Indexed keywords

ANDROGEN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033968439     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67815-9     Document Type: Article

References (28)

1. Kreis, W., Budman, D. R. and Calabro, A.: Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol, 79: 196, 1997
2. Speicher, L. A., Barone, L. and Tew, K. W.: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res, 52: 4433, 1992
3. Petrylak, D. P., MacArthur, R. B. and Shelton, G.: Phase I/II studies of the combination of estramustine and docetaxel in hormone-refractory prostate cancer. Semin Oncol, suppl. 17, 26: 28, 1999
4. Dahllof, B., Billstrom, A., Cabral, F. et al: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res, 53: 4573, 1993
5. Stearns, M. E., Wang, M., Tew, K. D. et al.: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol, suppl., 107: 2647, 1988
6. Speicher, L. A., Barone, L. R., Chipman A. E. et al: P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst, 86: 688, 1994
7. Yang, C. P., Shen, H. J. and Horwitz, S. B.: Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst, 86: 723, 1994
8. Pienta, K. J. and Lehr, J. E.: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol, 149: 1622, 1993
9. Cortes, J. E. and Pazdur, R.: Docetaxel. J Clin Oncol, 13: 2643, 1995
10. Ringel, I. and Horwitz, S. B.: Studies with RP 56975 (taxotere): a semisynthetic analogue of taxol. J Natl Canc Inst, 83: 288, 1991
11. Petrylak, D. P., Macarthur, R. B., O'Connor, J. et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 17: 958, 1999
12. Kreis, W., Budman, D. R., Fetten, J. et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol, 1: 33, 1999
13. Savarese, D. M., Taplin, M. E., Marchesani, B. et al: A phase II study of docetaxel, estramustine, and low dose hydrocortisone in hormone refractory prostate cancer. Proc Am Soc Clin Oncol, 18: 321A, 1999
14. Sinibaldi, V., Carducci, M., Moore-Cooper, S. et al: A phase II study evaluating a one day course of estramustine phosphate (EMP) and docetaxel (D) in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol, 18: 322A, 1999
15. Piccart, M. J., Klijn, J., Paridaens, R. et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol, 15: 3149, 1997
16. Tannock, I., Gospodarowicz, M., Meakin, W. et al: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol, 7: 590, 1989
17. Tannock, I. F., Osoba, D., Stockler, M. R. et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756, 1996
18. Sartor, O., Weinberger, M., Moore, A. et al: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology, 52: 252, 1998
19. Kantoff, P. W., Halabi, S., Conaway, M. et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol, 17: 2056, 1999
20. Dawson, N. A., Cooper, M. R., Figg, W. D. et al: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer, 76: 453, 1995
21. Kelly, W. K., Curley, T., Leibretz, C. et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol, 13: 2208, 1995
22. Storlie, J. A., Buckner, J. C. Wiseman, G. A. et al: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer, 76: 96, 1995
23. Bubley, G. J., Carducci, M., Dahut, W. et al: Eligibility and response guidelines for phase II clinical trial in androgen independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17: 3461, 1999
24. Simon, R.: Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 10: 1, 1989
25. Roth, B. J., Yeap, B. Y., Wilding, G. et al: Taxol in advanced hormone-refractory carcinoma of the phase II trial of the Eastern Cooperative Oncology Group. Cancer, 72: 2457, 1993
26. Hudes, G. R., Nathan, F., Khater, C. et al: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol, 15: 3156, 1997
27. Patel, S. R., Kvols, L. K., Hahn, R. G. et al: A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer, 66: 655, 1990
28. Mohler, J. L., Chen, Y., Hamil, K. et al: Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res, 2: 889, 1996